AVDL Insider Trading | Avadel Pharmaceuticals Buys and Sells

AVDL Insider Trading

Insider Ownership Percentage: 4.80%
Insider Buying (Last 12 Months): $526,363.04
Insider Selling (Last 12 Months): $0.00

Avadel Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Avadel Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Avadel Pharmaceuticals Share Price & Price History

Current Price: $8.03
Price Change: Price Decrease of -0.12 (-1.47%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for AVDL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$8.03Closing price on 04/20/25:

SEC Filings (Institutional Ownership Changes) for Avadel Pharmaceuticals (NASDAQ:AVDL)

69.19% of Avadel Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AVDL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$63kbought$110ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal InflowsTotal Outflows
Avadel Pharmaceuticals logo
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More on Avadel Pharmaceuticals

Today's Range

Now: $8.03
Low: $7.81
High: $8.15

50 Day Range

MA: $7.97
Low: $6.59
High: $8.99

52 Week Range

Now: $8.03
Low: $6.38
High: $19.09

Volume

1,099,648 shs

Average Volume

1,215,554 shs

Market Capitalization

$775.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Who are the company insiders with the largest holdings of Avadel Pharmaceuticals?

Avadel Pharmaceuticals' top insider investors include:
  1. Gregory J Divis (CEO)
  2. Peter J Thornton (Director)
  3. Thomas S Mchugh (CFO)
  4. Geoffrey Michael Glass (Director)
  5. Linda Palczuk (Director)
  6. Mark Anthony Mccamish (Director)
Learn More about top insider investors at Avadel Pharmaceuticals.

Who are the major institutional investors of Avadel Pharmaceuticals?

Avadel Pharmaceuticals' top institutional investors include:
  1. Rhumbline Advisers — 0.13%
  2. IMC Chicago LLC — 0.00%
  3. Edge Wealth Management LLC — 0.03%
Learn More about top institutional investors of Avadel Pharmaceuticals stock.

Which major investors are selling Avadel Pharmaceuticals stock?

Within the last quarter, AVDL stock was sold by these institutional investors:
  1. IMC Chicago LLC

Which major investors are buying Avadel Pharmaceuticals stock?

During the last quarter, AVDL stock was acquired by institutional investors including:
  1. Edge Wealth Management LLC
  2. Rhumbline Advisers
Within the last year, these company insiders have bought Avadel Pharmaceuticals stock:
  1. Gregory J Divis (CEO)
  2. Peter J Thornton (Director)
  3. Thomas S Mchugh (CFO)
  4. Geoffrey Michael Glass (Director)
  5. Linda Palczuk (Director)
Learn More investors buying Avadel Pharmaceuticals stock.